Fortive Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Fortive Corporation Common Stock trades at $56.82 (market cap $17.04B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: Fortive Corporation Common Stock is the larger of the two by market cap, and Fortive Corporation Common Stock pays a 0.5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FTV | XBI | |
|---|---|---|
Market Cap | $17.04B | $10.11B |
Volume | 2,190,596 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $64.09 | $169.55 |
52-Week Low | $47.80 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $20.17B | — |
Dividend Yield | 0.5% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →